Valeria Avdoshina

Valeria Avdoshina

Auto-generated profile, based on publicly available information

Valeria Avdoshina

Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20057, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2018 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
SDSimona Dedoni
Simona Dedoni
LCLee A. Campbell
Lee A. Campbell
BHBrandon K. Harvey
Brandon K. Harvey
VAValeria Avdoshina
Valeria Avdoshina
IMItalo Mocchetti
Italo Mocchetti

10 March 2017 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
VAValeria Avdoshina
Valeria Avdoshina
SCSeamus Caragher
Seamus Caragher
EWErin D. Wenzel
Erin D. Wenzel
FTFrancesca Taraballi
Francesca Taraballi
IMItalo Mocchetti
Italo Mocchetti
GHGaylia Jean Harry
Gaylia Jean Harry
The human immunodeficiency virus (HIV) envelope protein gp120 promotes axonal damage and neurite pruning, similar to that observed in HIV‐positive subjects with neurocognitive disorders. Thus, gp120 has been used to examine molecular and cellular pathways underlying HIV‐mediated neuronal dysfunction. Gp120 binds to tubulin beta III, a component of neuronal microtubules. Microtubule function, which modulates the homeostasis of neurons, is regulated by polymerization and post‐translational modifications. Based on these considerations, we tested the hypothesis that gp120 induces dynamic instability of neuronal microtubules. We first observed that gp120 prevents the normal polymerization of tubulin in vitro. We then tested whether gp120 alters the post‐translational modifications in tubulin by examining the ability of gp120 to change the levels of acetylated tubulin in primary rat neuronal cultures. Gp120 elicited a time‐dependent decrease in tubulin acetylation that was reversed by Helix‐A peptide, a compound that competitively displaces the binding of gp120 to neuronal microtubules. To determine whether post‐translational modifications in tubulin also occur in vivo, we measured acetylated tubulin in the cerebral cortex of HIV transgenic rats (HIV‐tg). We observed a decrease in tubulin acetylation in 5‐ and 9‐month‐old HIV‐tg rats when compared to age‐matched wild type. Neither changes in microglia morphology nor alterations in mRNA levels for interleukin‐1β and tumor necrosis factor α were detected in 5‐month‐old animals. Our findings propose neuronal microtubule instability as a novel mechanism of HIV neurotoxicity, without evidence of enhanced inflammation. image

28 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
SDSimona DEDONI
Simona DEDONI
VAValeria Avdoshina
Valeria Avdoshina
CCChiara Camoglio
Chiara Camoglio
CSCarlotta Siddi
Carlotta Siddi
WFWalter Fratta
Walter Fratta
PFPaola Fadda
Paola Fadda
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic that might lead to very serious consequences. Notably, mental status change, brain confusion, and smell and taste disorders along with neurological complaints have been reported in patients infected with SARS-CoV-2. Furthermore, human brain tissue autopsies from COVID-19 patients show the presence of SARS-CoV-2 neuroinvasion, which correlates with the manifestation of meningitis, encephalitis, leukocyte infiltration, and neuronal damage. The olfactory mucosa has been suggested as a way of entry into the brain. SARS-CoV-2 infection is also known to provoke a hyper-inflammatory reaction with an exponential increase in the production of pro-inflammatory cytokines leading to systemic responses, even in the absence of direct infection of brain cells. Angiotensin-converting enzyme 2 (ACE2), the entry receptor of SARS-CoV-2, has been extensively demonstrated to be present in the periphery, neurons, and glial cells in different brain regions. To dissect the details of neurological complications and develop therapies helping COVID-19 survivors regain pre-infection quality of life, the development of robust clinical models is highly warranted. Several human angiotensin-converting enzyme 2 (hACE2) transgenic mouse models have been developed and used for antiviral drug screening and vaccine development, as well as for better understanding of the molecular pathogenetic mechanisms of SARS-CoV-2 infection. In this review, we summarize recent results from the studies involving two such mouse models, namely K18- and CAG-hACE2 transgenics, to evaluate the direct and indirect impact of SARS-CoV-2 infection on the central nervous system.

30 April 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
SDSimona DEDONI
Simona DEDONI
VAValeria Avdoshina
Valeria Avdoshina
MOMaria C. Olianas
Maria C. Olianas
POPierluigi Onali
Pierluigi Onali
Lysophosphatidic acid (LPA), a bioactive lipid molecule, has been identified as a critical regulator of several cellular processes in the central nervous system, with significant impacts on neuronal function, synaptic plasticity, and neuroinflammatory responses. While Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease have garnered considerable attention due to their incidence and socioeconomic significance, many additional neurological illnesses remain unclear in terms of underlying pathophysiology and prospective treatment targets. This review synthesizes evidence linking LPA’s function in neurological diseases such as traumatic brain injury, spinal cord injury, cerebellar ataxia, cerebral ischemia, seizures, Huntington’s disease, amyotrophic lateral sclerosis, Hutchinson-Gilford progeria syndrome, autism, migraine, and human immunodeficiency virus (HIV)-associated complications Despite recent advances, the specific mechanisms underlying LPA’s actions in various neurological disorders remain unknown, and further research is needed to understand the distinct roles of LPA across multiple disease conditions, as well as to investigate the therapeutic potential of targeting LPA receptors in these pathologies. The purpose of this review is to highlight the multiple functions of LPA in the aforementioned neurological diseases, which frequently share the same poor prognosis due to a scarcity of truly effective therapies, while also evaluating the role of LPA, its receptors, and signaling as promising actors for the development of alternative therapeutic strategies to those proposed today.

6 October 2021 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
VAValeria Avdoshina
Valeria Avdoshina
FYFutoshi Yumoto
Futoshi Yumoto
IMItalo Mocchetti
Italo Mocchetti
SLScott L. Letendre
Scott L. Letendre
RTRochelle E. Tractenberg
Rochelle E. Tractenberg

30 November 2020 in AIDS
Verified
Journal Article
Closed access
VAValeria Avdoshina
Valeria Avdoshina
IMItalo Mocchetti
Italo Mocchetti